How Does a Molecule Become a Medicine? Drug Discovery & Clinical Trials

Added:

Reverse Pharmacology: The Bedside-to-Bench Alternative

The traditional drug discovery pipeline follows a 'bench-to-bedside' model, starting with laboratory target identification, moving to preclinical animal testing, and finally to human clinical trials. A major alternative to this high-cost, high-failure-rate process is 'Reverse Pharmacology' (or 'bedside-to-bench'). This paradigm begins with documented efficacy and safety data from traditional, natural, or folk medicine already used in human populations. Researchers then work backward to isolate the active compounds, understand their mechanisms, and optimize them. Proponents argue this approach significantly reduces the time, cost, and high attrition rate of early-stage drug discovery by starting with molecules that have already demonstrated therapeutic effects in humans, challenging the necessity of the standard synthetic-first, high-throughput screening pipeline.

Basic principles of cell biology and biochemistry, particularly how receptors and ligands interact to transmit signals within the body.
Fundamentals of organic chemistry, including molecular structures, functional groups, and chemical bonding.
An understanding of human physiology and pathology, specifically how diseases alter normal bodily functions at a cellular level.
Basic scientific methodology, including the concept of experimental controls, hypotheses, and the distinction between in vitro and in vivo testing.
Pharmacokinetics and pharmacodynamics (ADME), detailing how the body processes a drug and how the drug affects the body over time.
The regulatory approval process (such as by the FDA or EMA), including New Drug Applications (NDA) and post-market safety surveillance (Phase IV trials).
Advanced biotechnological methods in drug design, such as computer-aided drug design (CADD), high-throughput screening, and AI-driven molecule discovery.
Bioethics in clinical research, covering the history and implementation of informed consent, institutional review boards (IRBs), and equitable clinical trial design.
1.5K views0likes1:02:02@PintofScienceOriginal Release: 2021-05-20

Developing a medicine from a molecule to an authorized drug is a complex, multi-stage process spanning over a decade and costing billions of dollars, involving target identification, high-throughput screening, iterative optimization, pre-clinical testing, and three phases of clinical trials (Phase I focusing on safety, Phase II on efficacy and dosing, and Phase III on large-scale validation), with significant attrition rates throughout the process despite advances in chemistry, biology, and computational methods.